Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma

Jifang Zhou; Karen Sweiss; Jin Han; Naomi Y Ko; Pritesh R Patel; Brian C-H Chiu; Gregory S Calip

doi:10.1001/jamanetworkopen.2021.18410

Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma

JAMA Netw Open. 2021 Jul 1;4(7):e2118410. doi: 10.1001/jamanetworkopen.2021.18410.

Authors

Jifang Zhou^{1

2}, Karen Sweiss³, Jin Han³, Naomi Y Ko⁴, Pritesh R Patel⁵, Brian C-H Chiu⁶, Gregory S Calip¹

Affiliations

¹ Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago, Chicago.
² School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
³ Department of Pharmacy Practice, University of Illinois at Chicago, Chicago.
⁴ Section of Hematology Oncology, Boston University School of Medicine, Boston, Massachusetts.
⁵ Division of Hematology and Oncology, University of Illinois at Chicago, Chicago.
⁶ Department of Public Health Sciences, The University of Chicago, Chicago, Illinois.

Abstract

This cohort study examines the risk of skeletal-related events associated with the frequency of bisphosphonate treatment in patients with multiple myeloma.

Publication types

Evaluation Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Intravenous
Adult
Aged
Bone Density Conservation Agents / administration & dosage*
Bone Diseases / etiology
Bone Diseases / prevention & control*
Chemoprevention
Diphosphonates / administration & dosage*
Drug Administration Schedule
Female
Fractures, Bone / etiology
Fractures, Bone / prevention & control
Humans
Hypercalcemia / etiology
Hypercalcemia / prevention & control
Male
Middle Aged
Multiple Myeloma / complications
Multiple Myeloma / drug therapy*
Recurrence
Retrospective Studies
Spinal Cord Compression / etiology
Spinal Cord Compression / prevention & control
Treatment Outcome

Substances

Bone Density Conservation Agents
Diphosphonates